NanoVibronix Shares Surge 32.76% Amid Compliance News
By ATTN Desk · Editorial oversight: Sean Han
NanoVibronix Inc. (NASDAQ: NAOV)
NanoVibronix Inc. is a medical device company specializing in non-invasive therapeutic ultrasound technologies. Headquartered in Elmsford, New York, with research and development in Nesher, Israel, the company develops patch-based and catheter-based devices designed to deliver localized, low-frequency, low-intensity ultrasound for pain relief and infection control.
Corporate Structure and Leadership
- Headquarters: Elmsford, NY (U.S.); R&D in Nesher, Israel
- Employee Count: 11–50 (LinkedIn)
- Founders: Harold Jacob; Jona Zumeris, Ph.D.
- Key Executives:
- Brian Murphy, Chief Executive Officer
- Steve Brown, Chief Financial Officer
- Lindsey Harrison, Vice President of Sales
The company’s patented surface acoustic wave (SAW) technology underpins wearable devices such as PainShield® (FDA-cleared; CE Mark) and WoundShield™ (CE Mark), as well as catheter coatings UroShield™ and NG-Shield™ (both CE Mark).
Developments and News
- April 9, 2025: Nasdaq confirmed NanoVibronix’s compliance with the $1.00 bid price and $2.5 million shareholders’ equity requirements. The matter was closed, and the company remains subject to a Mandatory Panel Monitor until April 9, 2026.
- May 20, 2025: Filing of the Form 10-Q for the quarter ended May 20, 2025, with the U.S. Securities and Exchange Commission.
- June 9, 2025: Distribution of the PRE 14A proxy statement announcing a virtual special meeting of stockholders scheduled for July 2, 2025, to vote on corporate governance matters.
- June 10, 2025: Share price closed at $1.08 on the Nasdaq Capital Market, reflecting a 32.76% increase with a trading volume of 4,489,583 shares.
Financial and Strategic Analysis
As of market close on June 10, 2025, key metrics include:
| Metric | Value |
|---|---|
| Share Price | $1.08 |
| Daily Change (June 10) | +32.76% |
| Volume (June 10) | 4,489,583 |
| Market Capitalization | $2.10 million |
| Revenue (TTM) | $2.66 million |
| Net Income (TTM) | −$5.61 million |
| Profit Margin | −210.82% |
| Price/Sales (TTM) | 0.12 |
| Price/Book (MRQ) | 0.06 |
| Total Cash (MRQ) | $601 thousand |
| Debt/Equity (MRQ) | 10.98% |
Strategic initiatives include:
- Expanding product commercialization in the United States, Europe, Australia, India, and Israel.
- Advancing clinical and regulatory pathways for new applications of therapeutic ultrasound.
- Enhancing shareholder engagement through virtual meeting formats and governance updates.
Market Position and Industry Context
- Sector: Medical Equipment & Devices
- Primary Markets: Pain management, wound care, infection control
- Competitive Landscape: Competes with larger multinational medical device firms and emerging ultrasound therapy companies
- Regulatory Status: FDA clearance for PainShield®; CE Mark for PainShield®, WoundShield™, UroShield™, NG-Shield™
- Applications:
- Reduction of catheter-associated urinary tract infections (CAUTI)
- Non-opioid pain relief
- Wound healing support
NanoVibronix’s technology addresses trends toward non-pharmacological therapies and at-home treatment models.
tl;dr
- On April 9, 2025, Nasdaq confirmed continued listing compliance; Mandatory Panel Monitor in place until April 9, 2026.
- Form 10-Q filed May 20, 2025; proxy statement issued June 9, 2025 for a virtual meeting on July 2, 2025.
- June 10, 2025 share price rose 32.76% to $1.08 on volume of 4.49 million.
- Full-year metrics show $2.66 million revenue, −$5.61 million net loss, 0.12 price/sales ratio.